(Q38832367)

6 September 2017

1 reference

title

Hybrid antibiotics - clinical progress and novel designs (English)

1 reference

6 September 2017

0 references

Alastair L Parkes

1

1 reference

PubMed ID

27169483

6 September 2017

Ian A Yule

series ordinal

2

1 reference

PubMed ID

27169483

6 September 2017

language of work or name

English

0 references

publication date

12 May 2016

1 reference

Expert Opinion on Drug Discovery

6 September 2017

1 reference

6 September 2017

11

1 reference

6 September 2017

7

1 reference

6 September 2017

665-680

1 reference

How the threat of antibiotic apocalypse helped a pharmacist find her voice

6 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

What Is an Antibiotic or an Antibiotic Substance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Alternatives to antibiotics—a pipeline portfolio review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Challenges and future prospects of antibiotic therapy: from peptides to phages utilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Understanding the mechanisms and drivers of antimicrobial resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Multiresistant Gram-negative infections: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Platforms for antibiotic discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

An analysis of FDA-approved drugs for infectious disease: antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Has the era of untreatable infections arrived?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Clinical management of resistance evolution in a bacterial infection: A case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Contribution of β-lactamases and porin proteins OmpK35 and OmpK36 to carbapenem resistance in clinical isolates of KPC-2-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Siderophore-drug complexes: potential medicinal applications of the 'Trojan horse' strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Combination approaches to combat multidrug-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Lowenstein-Jensen selective medium for reducing contamination in Mycobacterium tuberculosis culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Combination drugs, an emerging option for antibacterial therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Combination therapy for treatment of infections with gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Antibiotic interactions that select against resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Drug interactions modulate the potential for evolution of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Drug interactions and the evolution of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Multifunctional compounds: smart molecules for multifactorial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Clostridium difficile drug pipeline: challenges in discovery and development of new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Outer membrane protein alterations and blaTEM-1 variants: their role in -lactam resistance in Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Rifamycin-mode of action, resistance, and biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Ecological impact of MCB3837 on the normal human microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Adjuvants Based on Hybrid Antibiotics Overcome Resistance in Pseudomonas aeruginosa and Enhance Fluoroquinolone Efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Novel 3-arylfuran-2(5H)-one-fluoroquinolone hybrid: design, synthesis and evaluation as antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Determination of the primary molecular target of 1,2,4-triazole-ciprofloxacin hybrids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Search for factors affecting antibacterial activity and toxicity of 1,2,4-triazole-ciprofloxacin hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Novel antibacterial active quinolone-fluoroquinolone conjugates and 2D-QSAR studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Novel hybrids of metronidazole and quinolones: synthesis, bioactive evaluation, cytotoxicity, preliminary antimicrobial mechanism and effect of metal ions on their transportation by human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Ionization of carbon acids in liquid ammonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Development and evaluation of a highly reliable assay for SUMO-specific protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Synthesis and study of antibacterial activities of antibacterial glycopeptide antibiotics conjugated with benzoxaboroles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Design, synthesis, and evaluation of novel fluoroquinolone-flavonoid hybrids as potent antibiotics against drug-resistant microorganisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Enterobactin-mediated delivery of β-lactam antibiotics enhances antibacterial activity against pathogenic Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

Design of Bifunctional Antibiotics that Target Bacterial rRNA and Inhibit Resistance-Causing Enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17460441.2016.1187597

10.1080/17460441.2016.1187597

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27169483